Kornimate/medical-research-clean huggingface dataset:
treatment of fever due to malaria with ibuprofen

Conditions: Fever

Summary: drugs to treat fever are widely used in children with fever. but there is a controversy about the benefit of reducing fever in children with malaria. ibuprofen is often used to treat malarial fever. this study evaluates the capacity of ibuprofen to reduce fever in malaria. the effect of ibuprofen on fever compared to only mechanical measures is investigated in children with malaria.

fever is the most apparent clinical manifestation of plasmodium falciparum infection during the acute phase. the role of fever in defence against malaria or in other infectious diseases remains unclear. however, it has been shown that febrile temperatures inhibit the growth of p. falciparum in vitro. antipyretic drugs are commonly and widely used to treat malarial fever in endemic areas. there is however a controversy about the benefit of reducing fever in children with malaria. data from gabon have revealed that neither paracetamol, nor naproxen or metamizol - antipyretics often used in this area - had an effect on fever clearance time. worryingly, paracetamol increased parasite-clearance times (i.e. inhibited clearance of parasites) and decreased significantly the production of oxygen radicals and tumour necrosis factor (tnf), mechanisms of the innate immune response, pivotal to combat infections. another antipyretic drug often used to treat malarial fever in endemic areas is ibuprofen. however, the rationale of its use and its capacity of reducing fever due to p. falciparum infections has never been proven in this area. comparison: the effect of ibuprofen plus mechanical fever "treatment" (continuous fanning, tepid sponging, and cooling blankets) is compared to mechanical treatment alone to treat fever in children with malaria.

Eligibility criteria:
inclusion criteria: * uncomplicated falciparum malaria * asexual parasitaemia between 20,000 and 200,000/µl * fever with temperature above 38 °c or history of fever during the preceding 24 hours * informed consent exclusion criteria: * effective anti-malarial treatment for the present attack * antipyretic use within 6 hours of presentation * contraindications to the use of ibuprofen (history of asthma, dyspeptic symptoms, gastro-intestinal bleeding, or allergy to ibuprofen) * mixed plasmodial infection * haemoglobin \< 7 g/dl * packed-cell volume \< 20% * white cell count \> 16,000/l * platelet count \< 40,000/µl * schizontaemia \> 50/µl * impaired consciousness * convulsions or history of convulsions * concomitant diseases masking assessment of response

Keywords: malaria fever ibuprofen gabon
guided meditation during radiotherapy.

Conditions: Quality of Life; Relaxation During Radiation Therapy; Cancer; Radiation Toxicity

Summary: the purpose of this research is to gather information on the effects of mindfulness-based intervention (mbi) on quality of life during and after radiation treatment. this study involves randomization. there is a 50 percent chance (like a flip of the coin) that you will be randomized to attend meditation sessions during treatment.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * prescribed a course of at least 15 daily fractions of rt for curative intent of any malignancy * willing to attend mbi sessions weekly during rt * able to transport themselves to scheduled mbi sessions in the dahlc * able to complete questionnaire(s) by themselves * native english speaker (mbi sessions, videos, and qol questionnaires are only available in english) * ecog performance status 0-2 exclusion criteria: * prescribed a course of rt with fewer than 15 consecutive, daily fractions * unable or unwilling to attend required mbi sessions
rebreathing of carbon dioxide with a device used for giving inhalational anaesthesia

Conditions: Anesthetic Ventilatory Requirements

Summary: the anesthesia gas reflector (anaconda) is built on the adsorptive capacity of active carbon which also adsorbs carbon dioxide in exhaled air. rebreathing of carbon dioxide thus occurs and must be compensated for by increased ventilation. this study aims at determining how much compensation must be given, based on the hypothesis that rebreathing depends on carbon dioxide level in blood and exhaled air.


Eligibility criteria:
inclusion criteria: * elective coronary artery by-pass graft surgery * elective valve replacement surgery * normal left ventricular ejection fraction on preoperative echocardiography exclusion criteria: * obstructive lung disease * restrictive lung disease

Keywords: quantification ventilatory requirements charcoal filter
tecfidera lymphocyte chart review

Conditions: Multiple Sclerosis

Summary: the primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on cd4+ and cd8+ t cells, in participants on tecfidera therapy for at least 6 months. the secondary objective is to investigate changes in lymphocyte subtypes other than cd4+ and cd8+ t cells.


Eligibility criteria:
key inclusion criteria: * initiated tecfidera treatment for the first time on or after 27 march 2013 and received at least 6 months of continuous treatment with tecfidera * clinical diagnosis of a relapsing form of ms * a baseline measurement for alc and absolute cd4+ or cd8+ count within 6 months prior to tecfidera initiation * at least 1 measurement for alc and absolute cd4+ or cd8+ count while on tecfidera therapy for at least 6 months key exclusion criteria: * clinical diagnosis of human immunodeficiency virus (hiv) or acquired immunodeficiency syndrome (aids) prior to tecfidera initiation * participation in define 109ms301 (nct00420212) or confirm 109ms302 (nct00451451) note: other protocol-defined inclusion/exclusion criteria may apply.

Keywords: lymphocyte serious infections opportunistic infections relapsing forms
comparative study to assess an advanced skin protectant in the management of incontinence-associated dermatitis

Conditions: Incontinence-associated Dermatitis

Summary: the purpose of the clinical study is to assess the effects of 3m cavilon advanced skin protectant in comparison to different local iad care regimes in hospitals (iad: incontinence-associated dermatitis)

the purpose of the clinical study is to assess the effects of 3m cavilon advanced skin protectant in comparison to different local iad care regimes in hospitals (iad: incontinence-associated dermatitis). iad is a skin damage caused by exposure to moisture and irritants such as urine and/or stool. the clinical appearance ranges from painful erythema to severe erosion and denudation/skin loss with or without secondary infection. the durable, long lasting skin protectant (3m study device) is formulated to attach to moist or wet skin surfaces (i.e., superficial, partial thickness skin loss) to provide better protection against moisture and irritants under challenging conditions.

Eligibility criteria:
inclusion criteria: 1. is the patient 18 years or older? 2. has the patient or their legally authorized representative signed the informed consent form? 3. does the patient have iad category 1a (iad 1a: persistent redness without clinical signs of infection) or iad category 2a (iad 2a: skin loss without clinical signs of infection) in the study area (study area: the sacral region going down to the upper thighs, bordered approximately 5 cm below the gluteal fold? 4. is the patient incontinent and does stool and/or urine come into direct contact with the skin? 5. is the patient able to be turned/positioned with regard to skin assessment and photo documentation? 6. is there a reasonable expectation that the patient will remain in the hospital setting for at least 7 days? exclusion criteria: 1. is the patient pregnant or breast feeding? 2. does the patient have a known hypersensitivity or allergy to acrylate or cyanoacrylate? 3. does the patient have a stage ii, iii, iv or unstageable pressure ulcer or other suspected deep tissue injury in the study area? 4. does the patient require topical treatment due to a fungal, bacterial or viral infection in the study area? 5. does the patient require treatment with topical medication or product other than iad treatment in the study area? 6. does the patient have any other local dermatological disease or skin condition interfering with this study? 7. does the patient have any medical condition (e.g. end of life, planned elective surgery) that in the opinion of the investigator should exclude him/her from participating in the study? 8. does the patient participate in another study with a known or implied effect on skin barrier function?
emergence delirium and recovery time in children

Conditions: Emergence Delirium

Summary: in this study, inhalation anesthesia procedure and intravenous anesthesia method will be compared in terms of emergence delirium and recovery time in children who are scheduled for dental treatment under general anesthesia.

pediatric anesthesia early delirium scale (paeds) will be used to evaluate postoperative emergence delirium.

Eligibility criteria:
inclusion criteria: 1. indication of dental treatment under general anesthesia. 2. no systemic disease (asa1). 3. child and parent agree to participate in the work exclusion criteria: 1. do not accept to participate in the work. 2. the child is not systemically healthy. 3. children with allergies to general anesthetic drugs. 4. contraindicated children to take general anesthesia 5. children with upper respiratory tract infection on the day of operation
prospective, randomised multicenter study comparing the efficacy of transbronchial forceps biopsy with cryobiopsy to diagnose interstitial lung disease.

Conditions: Interstitial Lung Disease

Summary: the use of cryoprobes improves the diagnostic yield in transbronchial biopsies compared to forceps biopsies to diagnose an interstitial lung disease

endoscopic biopsy currently plays only a minor role for the diagnosis of interstitial lung disease. however, in some cases obtaining lung tissue is necessary to establish a final diagnosis. the current standard procedure is transbronchial forceps biopsy - if not sufficient: surgical lung biopsy. transbronchial lung biopsy bears essential limitations however: * small tissue sample * limited evaluability of the material caused by forceps-induced crush artifacts in cryobiopsy the cryoprobe´s tip is being cooled and thereby cools the surrounding tissue to approximately minus 89 degrees celsius. subsequently, the frozen probe is retracted with the frozen tissue being attached onto the frozen probe's tip. when applied in the central airways, cryobiopsy proved to deliver large specimens of good quality, which may exceed forceps biopsies in terms of diagnostic yield. pilot studies on transbronchial cryobiopsy showed that same advantages as seen in the endobronchial use.

Eligibility criteria:
inclusion criteria: 1. clinical indications for biopsy of interstitial lung disease 2. age over 18 years 3. signed consent exclusion criteria: 1. risk of bleeding / ongoing anticoagulation 2. oxygen saturation \<90% - despite delivery of 2l oxygen / min 3. underlying cardiac disease (unstable angina, myocardial infarction during the last month, congestive heart failure) 4. pulmonary hypertension, pap sys\> 50mmhg

Keywords: interstitial lung disease transbronchial biopsy cryobiopsy
safety and the pharmacokinetic study of characteristics of mkt-n2 (montelukast) and singulair® (montelukast sodium)to treat asthma

Conditions: Asthma and Allergic Rhinitis

Summary: the purpose of a center, randomized, open label, single dose, placebo-controlled, 2-treatment, 2-way, 2-period crossover study to compare the safety and the pharmacokinetic characteristics of mkt-n2 (montelukast) and singulair® (montelukast sodium) tablet 10mg in healthy male korean subjects


Eligibility criteria:
inclusion criteria: * healthy korean male over20, under 45 years old * 55kg over weight, ibw +-20% range male exclusion criteria: * males who have gotten a clinically significant of liver, pancreas, kidneys, nervous system, respiratory system, endocrine system, blood cancer, mental illness, cardiovascular, urinary tract disease, or a history corresponding * males who have gotten a history of gastrointestinal disease * males who have gotten a history of hypersensitivity to montelukast or reaction to other drugs(aspirin, antibiotics)
neuroprotection and repair in optic neuritis

Conditions: Multiple Sclerosis; Optic Neuritis

Summary: the primary aim of this open-label pilot trial is to estimate the treatment effect of 100 mg of oral minocycline twice daily for 90 days, initiated within 30 days of onset of on, on functional and structural optic nerve recovery compared to no treatment. the primary outcome measure that will be used to measure optic nerve recovery is retinal nerve fibre layer (rnfl) thickness. other objectives: secondary outcomes are temporal rnfl thickness, macular volume, and visual outcomes.


Eligibility criteria:
inclusion criteria: * age between 18 and 60 years, the lower age limit has been set for safety purposes to avoid exposing children and adolescents to unproven therapies at least early in their development, the upper limit is set because the specificity of the diagnosis of on is likely reduced in older individuals * onset of on within the previous 30 days * intention to continue current multiple sclerosis (ms) disease modifying therapy (if any) for at least 6 months (glatiramer acetate, interferon beta) and not start, or switch to, a new therapy * sexually active participants of child-bearing potential must agree to use adequate contraception * willingness to provide written informed consent exclusion criteria: * coexistence of any disease other than ms that could be responsible for on or better explains their signs and symptoms. this would include patients with other suspected or established causes of vision loss including glaucoma, maculopathies, amblyopia, neuro-myelitis optica (nmo), and other optic neuropathies * clinically significant liver, renal, or bone marrow dysfunction * any condition that could interfere with any evaluation in the study including patients who are unable to undergo reliable oct testing due to dense media opacities or severe nystagmus in whom appropriate fixation cannot be attained * concurrent or prior use of corticosteroids during this episode of optic neuritis * concurrent participation in any clinical therapeutic trial * use within the previous 12 months of any of the following: natalizumab, mitoxantrone, cyclophosphamide, azathioprine, cyclosporine, methotrexate, or any other immunomodulating or immunosuppressive drug including other recombinant or non-recombinant cytokine or any experimental therapy known to effect immune function * use within the previous 6 months of minocycline or another tetracycline or use of either for ms at any time * any other condition or situation that in the opinion of the investigator would either put the patient at risk of worsening health if enrolled in the trial or would prevent completion of the trial with complete follow-up.

Keywords: minocycline retinal nerve fibre layer thickness macular volume visual outcomes
clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in participants with schizophrenia

Conditions: Schizophrenia

Summary: 1. to evaluate the efficacy and safety of cariprazine at a target dose of 4.5 milligram per day (mg/d) compared with placebo in prevention of relapse in patients with schizophrenia 2. to evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia for a minimum of 1 year before visit 1 (screening). * ability to follow study instructions, complete study assessment tools with minimal assistance and no alteration to the assessment tools, and likely to complete all required visits. * participant meets diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) criteria for schizophrenia as determined by structured clinical interview for dsm-5 (scid-5). * positive and negative syndrome scale (panss) total score \>= 70 and \<= 120 at visit 1 and visit 2 (day 1). * rating of at least 4 (moderate) on at least 2 of the following 4 panss positive symptoms; p1: delusions; p2: conceptual disorganization; p3: hallucinatory behaviour; p6: suspiciousness/persecution at visit 1 and visit 2. exclusion criteria: * currently meeting dsm-5 criteria for any of the following: * schizoaffective disorder, schizophreniform disorder, and other psychotic disorders * bipolar i and ii disorder * autism spectrum disorder, intellectual development disorder, delirium, major/minor neurocognitive disorder * history of meeting dsm-5 criteria for substance-related disorders (excluding caffeine-related and tobacco-related disorders) within the prior 3 months before visit 1. * prior participation in any clinical trials involving experimental or investigational drugs within 6 months before visit 1 or planned during the study. * female participants who are pregnant, planning to become pregnant during the course of the study, or are currently lactating.
nexalin therapy for the treatment of depressive symptoms

Conditions: Depression

Summary: the primary objectives of this phase ii study are to demonstrate the safety of nexalin therapy and to investigate the efficacy of nexalin therapy.

this randomized, double-blind, placebo-controlled, multi-center trial has 3 different treatment arms. study tools: * hamilton depression rating scale (ham-d21) * clinical global impressions (cgi) * montgomery-asberg depression rating scale (madrs) * beck's depression inventory * hamilton anxiety rating scale (ham-a) * hospital anxiety and depression scale (hads)

Eligibility criteria:
inclusion criteria: * diagnosed with mild to moderate depression episode, based on the ham-d21 rating scale (10-13 = mild; 14-17 = mild to moderate) * diagnosed with mild to moderate depression episode based on icd-10 diagnostic guidelines * is willing and able to spend 4 weeks as a hospital inpatient * is willing and able to return to the clinic during follow-up period exclusion criteria: * a ham-d21 rating scale of \ 17 * diagnosed outside of mild to moderate depression episode range based on the icd-10 diagnostic guidelines * unable to complete wash-out interval without taking antidepressants or psychotropic medications * is pregnant or may be pregnant * sensitivity to electrodes and/or their conductive gels or adhesives * break in skin integrity at the areas of electrode placement * currently taking immune suppressing drugs or suspected use of narcotics * presence of any implanted electronic devices, cardiac stimulator, or pacemaker * history of brain injury, including seizures, epilepsy, stroke, tumor of central nervous system, or hydrocephalus * history of heart attacks, congestive heart failure, or uncontrolled hypertension * history of schizophrenia or manic-depressive syndrome

Keywords: depression mild moderate anxiety kalaco scientific, inc.
open and laparoscopic total extraperitoneal repair under spinal anesthesia versus general anesthesia

Conditions: Pain, Postoperative; Postoperative Complications; Inguinal Hernia

Summary: inguinal hernia surgery is one of the most frequently performed procedures among general surgery cases. as with many open surgical methods, this repair is also performed laparoscopically. among these closed methods, the most frequently applied method is laparoscopic total extraperitoneal repair (tep). in general, this surgery is performed under general anesthesia (ga) in many centers. however, in cases where general anesthesia is inconvenient, local or other anesthesia methods are preferred. it has been stated in many studies in the literature that this surgery can be performed with methods other than general anesthesia. in a study of 480 patients, one of which was sinha et al., it was shown that this surgical procedure was successfully performed under spinal anesthesia (sa). in a prospective randomized study by dönmez et al., patients who underwent tep under general anesthesia and spinal anesthesia were compared. it has been reported that tep repair can be performed safely under sa and that sa is associated with less postoperative pain, better recovery, and better patient satisfaction than ga.2 in a retrospective study by yıldırım et al. it has been shown that there is significantly less need for analgesics and better patient satisfaction. there are also many meta-analyses made on this subject in the literature. compared with ga in these, sa was associated with a longer operative time, and postoperative pain and nausea and vomiting were less in sa. however, the risk of urinary retention in sa was significantly increased. it was observed that there was no significant difference in surgical complications such as seroma and wound infection. despite all these studies, until now, there is no clear consensus on which anesthesia should be used. the aim of the study is to show the effect of both the surgical method and the anesthesia method on the patient during surgery and in the early postoperative period in inguinal hernia

patients who underwent laparoscopic total extraperitoneal (tep) inguinal hernia repair and open surgical procedure (lichtenstein) with the diagnosis of inguinal hernia will be divided into 2 groups. general anesthesia (ga) will be applied to the 1st group, and ileoinguinal (ii) and ileohypogastric (ih) nerve block together with spinal anesthesia (sa) to the 2nd group.

Eligibility criteria:
inclusion criteria: * patients with inguinal hernias. * over 18 years old exclusion criteria: * younger than 18 years * those who have had previous abdominal surgery, * incarcerated or strangulated inguinal hernias, * recurrent hernias, * coagulopathies, * patients with musculoskeletal deformity, * those with chronic pain, * those who use drugs that affect the central nervous system daily, * those with a body mass index (bmi) over 40 kg/m2, * patients with contraindications to the recommended anesthetic technique.

Keywords: spinal anesthesia inguinal hernia general anesthesia laparoscopic total extraperitoneal repair